HUTCHMED (00013) Announces Publication of SACHI Phase III Study Results in The Lancet

HUTCHMED (00013) announced that the results of the SACHI Phase III study have been published in The Lancet.

SACHI is a Phase III study evaluating the combination therapy of savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®) for the treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients with MET amplification following disease progression after first-line EGFR tyrosine kinase inhibitor therapy.

Savolitinib is a potent, highly selective oral MET TKI co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

Osimertinib is an irreversible, third-generation EGFR TKI.

Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.

Professor Lu Shun, Co-Principal Investigator of the SACHI study and Director of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, stated: "The SACHI study data, now published in The Lancet, provide robust evidence that the combination of savolitinib and osimertinib significantly improves treatment outcomes for EGFR-mutated NSCLC patients with MET amplification.

These results underscore the combination therapy's ability to address MET amplification, a key resistance mechanism, offering clinically meaningful improvements for this challenging patient population.

We are particularly encouraged that consistent efficacy was also observed in patients previously treated with a third-generation EGFR TKI.

The savolitinib and osimertinib combination provides a sustained, all-oral regimen, offering a convenient and well-tolerated treatment option for patients in urgent need of new therapies."

Professor Wang Jie from the Chinese Academy of Medical Sciences Cancer Hospital is also a Co-Principal Investigator of the SACHI study.